Literature DB >> 22337990

Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003.

Jianwei Zhou1, Brigitte Lefebvre, Saul Deng, Rodica Gilca, Genevieve Deceuninck, Dennis K S Law, Philippe De Wals, Raymond S W Tsang.   

Abstract

In the era after the introduction of the meningococcal serogroup C conjugate vaccine, from 1 January 2003 to 31 December 2010, serogroup B meningococci were the major cause of invasive meningococcal disease in the province of Québec, Canada, being responsible for 72% of all meningococcal disease cases. Of the 334 invasive serogroup B Neisseria meningitidis strains analyzed, 53.9% belonged to the ST-269 clonal complex (CC). Since it first emerged in 2003, the percentage of invasive serogroup B isolates that belonged to the ST-269 CC had increased from 35% in 2003 to 76% in 2010. Among the 180 meningococci in the ST-269 CC, 91.7% belonged to a single ST (ST-269). The most common PorA genotypes identified in the ST-269 CC were (i) VR1 19-1, VR2 15-11, VR3 36 (84%) and (ii) VR1 18-7, VR2 9, VR3 35-1 (9%). Cases of invasive disease due to the ST-269 CC were commonly found in those aged 11 to 19 years (30.5%) and 20 to 40 years (25.5%). Meningococci of the ST-269 CC were uncommon in other Canadian provinces. In contrast to the ST-269 CC, invasive serogroup B meningococci that belonged to the ST-41/44 CC were much more diverse genetically. However, one ST (ST-571), which is uncommon in the United States, accounted for 35% of all cases due to this CC. The current finding suggests that the ST-269 clone may indeed represent an emerging hypervirulent clone of meningococci.

Entities:  

Mesh:

Year:  2012        PMID: 22337990      PMCID: PMC3347115          DOI: 10.1128/JCM.06835-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  54 in total

1.  Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread.

Authors:  J Jelfs; R Munro; E Wedege; D A Caugant
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

2.  An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2001-10-15

Review 3.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

4.  Analysis of PorA variable region 3 in meningococci: implications for vaccine policy?

Authors:  S C Clarke; M A Diggle; P Mölling; M Unemo; P Olcén
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

5.  Characterization of Neisseria meningitidis isolates collected from 1974 to 2003 in Japan by multilocus sequence typing.

Authors:  Hideyuki Takahashi; Toshiro Kuroki; Yuko Watanabe; Hiroshi Tanaka; Hiroo Inouye; Shiro Yamai; Haruo Watanabe
Journal:  J Med Microbiol       Date:  2004-07       Impact factor: 2.472

6.  Genetic analysis of Canadian isolates of C:2a:P1.2,5 and B:2a:P1.2,5 Neisseria meningitidis strains belonging to the hypervirulent clone of ET-15.

Authors:  Shaun Tyler; Raymond Tsang
Journal:  Can J Microbiol       Date:  2004-06       Impact factor: 2.419

7.  Capsule switching and capsule replacement in vaccine-preventable bacterial diseases.

Authors:  Raymond Tsang
Journal:  Lancet Infect Dis       Date:  2007-09       Impact factor: 25.071

Review 8.  Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.

Authors:  C E Frasch; W D Zollinger; J T Poolman
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

9.  Shift in the age-distribution of meningococcal disease as predictor of an epidemic?

Authors:  H Peltola; J M Kataja; P H Mäkelä
Journal:  Lancet       Date:  1982-09-11       Impact factor: 79.321

10.  Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada.

Authors:  Raymond S W Tsang; Chao Ming Tsai; Peixuan Zhu; Louise Ringuette; Manon Lorange; Dennis K S Law
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more
  16 in total

1.  Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009-2016.

Authors:  Rsw Tsang; L Hoang; G J Tyrrell; G Horsman; P Van Caeseele; F Jamieson; B Lefebvre; D Haldane; R R Gad; G J German; G Zahariadis
Journal:  Can Commun Dis Rep       Date:  2017-07-06

2.  Letter to the editor.

Authors:  Raymond Sw Tsang; Frances B Jamieson; Brigitte Lefebvre; Rodica Gilca
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

3.  Meningitis Vaccination, Knowledge, and Awareness Among YMSM in Chicago.

Authors:  Gregory Phillips; Amy K Johnson; Christian N Adames; Brian Mustanski
Journal:  Health Educ Behav       Date:  2018-01-11

4.  Immunization for meningococcal serogroup B: What does the practitioner need to know?

Authors:  Joan L Robinson
Journal:  Paediatr Child Health       Date:  2014-02       Impact factor: 2.253

5.  Increase in ST-11 serogroup W Neisseria meningitidis invasive meningococcal disease in Canada, 2016-2018.

Authors:  R S Tsang; L Hoang; G J Tyrrell; J Minion; P Van Caeseele; J V Kus; B Lefebvre; D Haldane; R Garceau; G German; G Zahariadis; B Hanley
Journal:  Can Commun Dis Rep       Date:  2019-06-06

6.  Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets.

Authors:  Dennis K S Law; Brigitte Lefebvre; Rodica Gilca; Saul Deng; Jianwei Zhou; Philippe De Wals; Raymond S W Tsang
Journal:  BMC Microbiol       Date:  2015-07-25       Impact factor: 3.605

7.  Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011.

Authors:  Y A Li; R Tsang; S Desai; H Deehan
Journal:  Can Commun Dis Rep       Date:  2014-05-01

8.  The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains.

Authors:  Rodica Gilca; Geneviève Deceuninck; Brigitte Lefebvre; Raymond Tsang; Rachid Amini; Vladimir Gilca; Monique Douville-Fradet; France Markowski; Philippe De Wals
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

9.  Parents' and adolescents' willingness to be vaccinated against serogroup B meningococcal disease during a mass vaccination in Saguenay-Lac-St-Jean (Quebec).

Authors:  Eve Dubé; Dominique Gagnon; Denis Hamel; Sylvie Belley; Hélène Gagné; Nicole Boulianne; Monique Landry; Julie A Bettinger
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 May-Jun       Impact factor: 2.471

10.  Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development.

Authors:  Carina Brehony; Caroline L Trotter; Mary E Ramsay; Manosree Chandra; Keith A Jolley; Arie van der Ende; Françoise Carion; Lene Berthelsen; Steen Hoffmann; Hjördís Harðardóttir; Julio A Vazquez; Karen Murphy; Maija Toropainen; Manuela Caniça; Eugenia Ferreira; Mathew Diggle; Giles F Edwards; Muhamed-Kheir Taha; Paola Stefanelli; Paula Kriz; Steve J Gray; Andrew J Fox; Susanne Jacobsson; Heike Claus; Ulrich Vogel; Georgina Tzanakaki; Sigrid Heuberger; Dominique A Caugant; Matthias Frosch; Martin C J Maiden
Journal:  Clin Vaccine Immunol       Date:  2014-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.